Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05987423




Registration number
NCT05987423
Ethics application status
Date submitted
5/07/2023
Date registered
14/08/2023
Date last updated
18/05/2025

Titles & IDs
Public title
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Scientific title
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease
Secondary ID [1] 0 0
2023-503309-13-00
Secondary ID [2] 0 0
GP44467
Universal Trial Number (UTN)
Trial acronym
SatraGO-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Thyroid Eye Disease 0 0
TED 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Satralizumab
Treatment: Drugs - Placebo

Experimental: Satralizumab - In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study

Placebo comparator: Placebo - In the part I period, participants will receive placebo q4w followed by proptosis response-based individualized treatment in part II of the study


Treatment: Drugs: Satralizumab
Satralizumab will be administered by SC injection.

Treatment: Drugs: Placebo
Placebo will be administered by SC injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving = 2mm Reduction in Proptosis from Baseline (Day 1) at Week 24 in the Study eye
Assessment method [1] 0 0
Provided there is no deterioration of proptosis \[= 2 millimeters (mm) increase\] in the fellow eye
Timepoint [1] 0 0
Baseline, Week 24
Secondary outcome [1] 0 0
Change in Proptosis
Assessment method [1] 0 0
Timepoint [1] 0 0
Baseline, Week 24, Week 48 and from Week 24 to Week 48
Secondary outcome [2] 0 0
Percentage of Participants Achieving = 1 Grade Reduction/Improvement in Diplopia Among Participants with Baseline Diplopia
Assessment method [2] 0 0
Timepoint [2] 0 0
Baseline, Week 24, Week 48
Secondary outcome [3] 0 0
Percentage of Participants Achieving Absence of Motility-induced Pain
Assessment method [3] 0 0
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
Percentage of Participants Achieving Absence of Spontaneous Pain
Assessment method [4] 0 0
Timepoint [4] 0 0
Week 24
Secondary outcome [5] 0 0
Percentage of Participants with a = 6 Point Improvement in the Visual Functioning and Appearance Sub-Scale Scores of the Graves Ophthalmopathy Quality of Life (GO-QoL)
Assessment method [5] 0 0
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16). Both the subscales and overall score are transformed to a scale of 0 to 100. Higher total scores indicate better QoL.
Timepoint [5] 0 0
Baseline, Week 24, Week 48 and from Week 24 to Week 48
Secondary outcome [6] 0 0
Percentage of Participants Achieving Overall Response
Assessment method [6] 0 0
Timepoint [6] 0 0
Week 24. Week 48
Secondary outcome [7] 0 0
Percentage of Participants Achieiving =2 Point Reduction in Clinical Activity Score (CAS) in the Study eye
Assessment method [7] 0 0
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica. Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms). Higher scores indicate worse symptoms.
Timepoint [7] 0 0
Baseline, Week 24, Week 48
Secondary outcome [8] 0 0
Percentage of Participants Acheiving CAS Value of 0 or 1 in the Study eye
Assessment method [8] 0 0
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica. Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms). Higher scores indicate worse symptoms.
Timepoint [8] 0 0
Week 24
Secondary outcome [9] 0 0
Percentage of Participants Achieving = 10 point Improvement in Ocular Surface Disease Index (OSDI) Overall Scores
Assessment method [9] 0 0
The OSDI instrument is a validated dry eye questionnaire and consists of three main sections concerning ocular symptoms, visual function, and environmental factors. It comprises of 12 questions and for every question, participants selects a number between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time" with totals of score ranging from 0 to 100. Higher scores represents a worse disease index.
Timepoint [9] 0 0
Baseline, Week 24
Secondary outcome [10] 0 0
Change in OSDI Ocular Symptoms and Vision-related Function Subscale Scores
Assessment method [10] 0 0
The OSDI instrument is a validated dry eye questionnaire and consists of three main sections concerning ocular symptoms, visual function, and environmental factors. It comprises of 12 questions and for every question, participants selects a number between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time" with totals of score ranging from 0 to 100. Higher scores represents a worse disease index.
Timepoint [10] 0 0
Baseline, Week 24
Secondary outcome [11] 0 0
Change in Oxford Corneal Staining Scores
Assessment method [11] 0 0
Oxford corneal staining chart consists of a 6 point scale. Staining assessment will be based on the intensity of fluorescein staining, ranging from Grade 0 to V for each panel (Grade 0-I: normal; Grade II-III: mild to moderate; Grade IV-V: severe). Higher grade indicates worse worse disease index.
Timepoint [11] 0 0
Baseline, Week 24
Secondary outcome [12] 0 0
Percentage of Participants Achieving = 2mm Reduction in Proptosis at Week 48 in the Study eye
Assessment method [12] 0 0
Timepoint [12] 0 0
Week 48
Secondary outcome [13] 0 0
Percentage of Participants Requiring Surgical Intervention for TED
Assessment method [13] 0 0
Timepoint [13] 0 0
Up to Week 48
Secondary outcome [14] 0 0
Percentage of Participants With Worsening of Proptosis by = 2 mm
Assessment method [14] 0 0
Timepoint [14] 0 0
Baseline, Week 48 and from Week 24 to Week 48
Secondary outcome [15] 0 0
Change in CAS
Assessment method [15] 0 0
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica. Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms). Higher scores indicate worse symptoms.
Timepoint [15] 0 0
Baseline, Week 48 and from Week 24 to Week 48
Secondary outcome [16] 0 0
Percentage of Participants with Adverse Events (AEs), with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE V5)
Assessment method [16] 0 0
Timepoint [16] 0 0
Baseline, Week 72
Secondary outcome [17] 0 0
Serum Concentration of Satralizumab
Assessment method [17] 0 0
Timepoint [17] 0 0
Up to Week 24

Eligibility
Key inclusion criteria
- Clinical diagnosis of TED based on CAS
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Decrease in CAS or proptosis of >= 2 points or >= 2 mm, respectively, in the study eye between Screening and Study Baseline (Day 1)
* Requiring immediate surgical ophthalmological intervention or planning corrective surgery or irradiation during the course of the study, in the judgment of the investigator
* Identified pre-existing ophthalmic disease that, in the judgment of the investigator, would preclude study participation or complicate interpretation of study results, including corneal decompensation unresponsive to medical management and including ophthalmic diseases that will likely require prohibited therapy during the study
* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of satralizumab

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/10/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2026
Actual
Sample size
Target
Accrual to date
Final
131
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Sydney Eye Hospital - Sydney
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Centre For Eye Research Australia - East Melbourne
Recruitment postcode(s) [1] 0 0
2000 - Sydney
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Kansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Utah
Country [9] 0 0
United States of America
State/province [9] 0 0
West Virginia
Country [10] 0 0
Argentina
State/province [10] 0 0
Capital Federal
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad Autonoma Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Ciudad Autónoma de Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Mendoza
Country [14] 0 0
Argentina
State/province [14] 0 0
Rosario
Country [15] 0 0
Austria
State/province [15] 0 0
Wien
Country [16] 0 0
Germany
State/province [16] 0 0
Berlin
Country [17] 0 0
Germany
State/province [17] 0 0
Dresden
Country [18] 0 0
Germany
State/province [18] 0 0
Essen
Country [19] 0 0
Germany
State/province [19] 0 0
Freiburg
Country [20] 0 0
Germany
State/province [20] 0 0
Münster
Country [21] 0 0
Germany
State/province [21] 0 0
Tübingen
Country [22] 0 0
Hong Kong
State/province [22] 0 0
Mongkok
Country [23] 0 0
Hungary
State/province [23] 0 0
Budapest
Country [24] 0 0
Italy
State/province [24] 0 0
Campania
Country [25] 0 0
Italy
State/province [25] 0 0
Lazio
Country [26] 0 0
Italy
State/province [26] 0 0
Lombardia
Country [27] 0 0
Italy
State/province [27] 0 0
Toscana
Country [28] 0 0
Japan
State/province [28] 0 0
Aichi
Country [29] 0 0
Japan
State/province [29] 0 0
Fukuoka
Country [30] 0 0
Japan
State/province [30] 0 0
Hokkaido
Country [31] 0 0
Japan
State/province [31] 0 0
Hyogo
Country [32] 0 0
Japan
State/province [32] 0 0
Kitakyushu-shi
Country [33] 0 0
Japan
State/province [33] 0 0
Kyoto
Country [34] 0 0
Japan
State/province [34] 0 0
Miyazaki
Country [35] 0 0
Japan
State/province [35] 0 0
Osaka
Country [36] 0 0
Japan
State/province [36] 0 0
Tokyo
Country [37] 0 0
Singapore
State/province [37] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number GP44467 www.roche.com/about_roche/roche_worldwide.htm
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. Only)
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05987423